Aprepitant + Palonosetron + Granisetron
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Leukemia
Conditions
Leukemia, Lymphoma
Trial Timeline
Nov 1, 2006 → Sep 1, 2009
NCT ID
NCT00415103About Aprepitant + Palonosetron + Granisetron
Aprepitant + Palonosetron + Granisetron is a approved stage product being developed by Merck for Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00415103. Target conditions include Leukemia, Lymphoma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00415103 | Approved | Completed |
Competing Products
20 competing products in Leukemia